Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. - Wikidata - wikimedia - TriplyDB

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.

http://www.wikidata.org/entity/Q42719353

about

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain Exploring Internal Ribosome Entry Sites as Therapeutic Targets From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport Antisense oligonucleotides: treating neurodegeneration at the level of RNA An Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNA Preclinical and clinical development of siRNA-based therapeutics Progress toward in vivo use of siRNAs-II Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA.Chemical modification: the key to clinical application of RNA interference?Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.Delivery is key: lessons learnt from developing splice-switching antisense therapies Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.Antisense gets a grip on miR-122 in chimpanzees.Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA.Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.Towards Fluorescence In Vivo Hybridization (FIVH) Detection of H. pylori in Gastric Mucosa Using Advanced LNA Probes.Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension Modulating Anti-MicroRNA-21 Activity and Specificity Using Oligonucleotide Derivatives and Length Optimization.Fluorescence In Vivo Hybridization (FIVH) for Detection of Helicobacter pylori Infection in a C57BL/6 Mouse Model Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.Small molecules targeting microRNA for cancer therapy: Promises and obstacles.DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing Potent inhibition of microRNA in vivo without degradation Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern.

P2860

Q24649633-C0FD1FF6-7E52-4946-A61D-A44ABA6642E3 Q26770355-2AAD32F0-F3D0-4C85-8347-6728B2ACB990 Q26779296-FB62C521-166A-4825-A85F-C839C15B3667 Q26997647-A7D6F422-7899-471D-92CD-42633EE6FDCB Q27007056-C5090DFC-9C03-4B98-98C9-7FD40CB19AB2 Q27664845-6460A693-5963-4EFC-88BD-EAF8C714077D Q28085290-AAF0ACEE-7465-4FF6-B6BD-37970FA42F3C Q28255877-8D7D5FD7-04CF-4896-B0DA-9DB06108526B Q28818017-8426D1A9-0F45-4899-A443-9728C82B595E Q28828761-A9184E89-1DA0-4EF6-8BE3-94CA73099310 Q30855431-B16AEEDD-780F-4553-A83C-950F13AA67E9 Q33286173-FB1BD262-7526-4563-8550-6BB25E934887 Q33308712-A2B6421C-CBEA-431D-B517-B4F01ADC54BA Q33418637-BD39E3C2-D63B-4FAC-A30F-0B44B4E9EE2C Q33625875-12894F89-3CE2-43BC-8F61-377C0D590BA4 Q33635469-7EFAE894-4A03-43BF-8D65-42077FB5B91D Q33750824-3B848653-B6E2-422F-95F1-FAABA39C2A3E Q34108728-E2830BEA-9B4D-4212-AF23-6F7D4164CEA1 Q34298059-15FBE319-3365-48D3-BAF8-8964A6110D37 Q34367048-11BA4C8D-C50D-429C-A085-6CABADB3A431 Q34448026-D87C46FC-3C65-49E4-B527-9CDE77FB7E4C Q34464418-DF3F936F-3EC5-46AA-8D96-348B5B1B2121 Q34499502-E8EB9E37-A92B-4336-8395-A2AE327ECDB8 Q34524329-B2DA349F-3819-4EB4-A69E-6E4C16A7E316 Q34559630-423EAA6F-7626-4D45-B768-1E1C6DBCD06D Q35154104-0E1C2CFA-3405-4861-8DAE-6D866D1C3D59 Q35615550-F10E79A3-891F-459C-AABA-A0DA8E718371 Q35770214-8D1C3A06-7165-4F16-BA2C-D0E87234CC62 Q35825430-5D5186CC-F011-4A75-A85A-BDC48576F5AC Q35915530-666D6FFE-EF00-42BE-8468-744EA79A975C Q36086300-2AB47237-1B90-4809-9A49-CE3857CA190F Q36160667-6715D20E-AE8C-4749-A862-605E1514FB9E Q36174842-A9610DAC-DADE-4C60-8837-3BFEBEDEEAB3 Q36296557-7C407571-9710-4B2B-8C48-4D4120321643 Q36449335-B467072D-1EDD-4E61-96C5-5842C77A0654 Q36532644-5A3E4776-2F5C-414C-815D-0D8DD60539D4 Q36567511-D0FF6060-0F59-41EC-AD3A-04D8BAE3EC8C Q37031903-F3D0A604-3652-4B25-8FDD-9BC1081FDC93 Q37041859-7A741D0D-C902-407A-8D7F-552C467310ED Q37139471-64BA4972-9D4F-4EAE-8E9B-69D543860964

P2860

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.

http://www.wikidata.org/entity/Q42719353

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@en

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@nl

type

label

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@en

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@nl

prefLabel

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@en

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@nl

P1433

Q42719353-DDF29A93-DA24-46FC-861C-703D07AF693D

P1476

Q42719353-6283E9B4-FDCB-4E7F-99B5-63104ADE69EA

P2093

Q42719353-01BD4590-2148-4A35-8BFF-D4BD2C216DD4

Q42719353-1706B7DF-3F58-45A9-A162-85765EC905F7

Q42719353-26491851-FF4E-4BC3-8953-BC5D47CB42FD

Q42719353-42E128C9-8661-47F7-83C4-2C9A3027A085

Q42719353-52F42462-F639-45B5-95F6-F2A3FBA4CBC6

Q42719353-ACE7C7F3-9242-4410-94CB-E868213A2E26

Q42719353-E26BF9AB-C622-4DE7-A34F-1D5460347620

Q42719353-FFE52226-B5A3-440F-9A02-1DD6DBCF7D92

P2860

Q42719353-0957DCC9-0815-4F9A-9C04-1BB9BA38A163

Q42719353-0C348269-7E93-413D-8233-ED8865472B7E

Q42719353-10367134-FD92-4D41-A481-351E11D60B08

Q42719353-127CC2E5-9036-4444-A40A-9BB0B650D563

Q42719353-1F16C28D-F3F3-4642-A7EE-264000058640

Q42719353-2F20DDAB-13AA-4681-86BD-41A2FF93EE94

Q42719353-355957EA-5DCD-42F6-9B7F-C04D282F87A0

Q42719353-3AFE46C2-C79E-4DDA-A4DA-70E830349CD2

Q42719353-454F943F-6219-4561-9B28-BF54763ADC9B

Q42719353-4629FE6C-C791-42FF-98D2-71E87615FE03

P304

Q42719353-5C84F8DD-69AC-42FF-988E-17092905122E

P31

Q42719353-24787FF6-3DA9-4A88-AD88-DE27CA1ED6DE

P356

Q42719353-CE597B6A-9635-4021-ACD1-6446C50D287F

P407

Q42719353-D6AC9185-8674-4E7C-AB2A-94568777DD40

P433

Q42719353-8DA96253-2F9B-4485-A8D0-DF8C3CA915B3

P478

Q42719353-D03F12A9-E591-4970-A46B-E307E4E57AE2

P577

Q42719353-E20BB3CD-F09F-4564-BF4A-2B724D344210

P5875

Q42719353-1046E5E0-13CE-48B7-9377-D5FDF5D91649

P698

Q42719353-D753286E-D715-4A0E-8327-44CE05E6CB15

P921

Q42719353-35423A09-AE3F-46EA-B77C-B3CDBC8D34B4

P932

Q42719353-2443D8E2-265C-4CD4-98F2-48A5F181A6A4

P356

P1433

Nucleic Acids Research

P1476

Antisense oligonucleotides con ...... ant hepatotoxicity in animals.

@en

P2093

Andrew M Siwkowski

http://www.w3.org/2001/XMLSchema#string

Brett P Monia

http://www.w3.org/2001/XMLSchema#string

C Frank Bennett

http://www.w3.org/2001/XMLSchema#string

Edward V Wancewicz

http://www.w3.org/2001/XMLSchema#string

Eric E Swayze

http://www.w3.org/2001/XMLSchema#string

Gene Hung

http://www.w3.org/2001/XMLSchema#string

Michael T Migawa

http://www.w3.org/2001/XMLSchema#string

Tadeusz K Wyrzykiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

p53 has a direct apoptogenic role at the mitochondria

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA

Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity

Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS

Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation

Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.

Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs.

Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis.

P304

687-700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NAR/GKL1071

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6617064

http://www.w3.org/2001/XMLSchema#string

P698

17182632

http://www.w3.org/2001/XMLSchema#string

P921

P932

1802611

http://www.w3.org/2001/XMLSchema#string